Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million ...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the presentation of new...
Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the selection ...
Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and Macroceutics, Inc., today announced the...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced it has expanded its ongoing...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the appointment of John...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it has appointed Dr....
Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs, which function via targeted protein degradation, today...
Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs which function via targeted protein degradation, today...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that data were presented by...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the publication of a...
NEW HAVEN, Conn., April 14, 2016 Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today...
Arvinas LLC, a biotechnology company creating a new class of oncology drugs based on protein degradation, announced the appointment of Angela Shen, M....
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it has three...
Arvinas LLC ("Arvinas"), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it ...
Arvinas, Inc. (a wholly owned subsidiary of Arvinas, LLC), a private biotechnology company creating a new class of drugs based on targeted protein...
Arvinas LLC ("Arvinas") today announced that it has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as ...
Arvinas LLC, a biotechnology company creating a new class of oncology drugs based on protein degradation, announced the appointment of Robert...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announces the publication of a joint...
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.